Transcode Therapeutics Inc RNAZ

US Biotechnology

$1.69 ▲ +2.42% (+$0.04)

🎈 Low Float

Open $1.60

Prev Close $1.65

Day Range $1.60 – $1.70

52W Range $1.58 – $20.99

Market Cap $28.61M

Beta 1.27

EPS (TTM) $-47.00

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2021-04-28
Shares Out.	1,060,000
Website	transcodetherapeutics.com/ ↗
Phone	13026587581
Employees	12
Revenue	$0
Gross Profit	$0
Net Income	-$6.8M
Free Cash Flow	-$22.6M
Total Assets	$151.0M
Total Liabilities	$12.7M
Equity	-$27.7M

About Transcode Therapeutics Inc

TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.

Transcode Therapeutics Inc is a publicly traded company under the ticker symbol RNAZ on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.